[
    [
        {
            "time": "2021-09-16",
            "original_text": "Novartis reports positive health-related quality of life data for 177Lu-PSMA-617 radioligand therapy in patients with advanced prostate cancer at ESMO 2021",
            "features": {
                "keywords": [
                    "Novartis",
                    "positive",
                    "health-related",
                    "quality",
                    "life",
                    "177Lu-PSMA-617",
                    "radioligand",
                    "therapy",
                    "advanced",
                    "prostate",
                    "cancer",
                    "ESMO"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-09-15",
            "original_text": "Zymeworks' Zanidatamab Aces Mid-Stage Esophageal Cancer Trial",
            "features": {
                "keywords": [
                    "Zymeworks",
                    "Zanidatamab",
                    "Aces",
                    "Mid-Stage",
                    "Esophageal",
                    "Cancer",
                    "Trial"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-09-14",
            "original_text": "Are You a Value Investor? This 1 Stock Could Be the Perfect Pick",
            "features": {
                "keywords": [
                    "Value",
                    "Investor",
                    "Stock",
                    "Perfect",
                    "Pick"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        }
    ]
]